Cost-effectiveness results in the base case.

*Cost for vaccinating adults and adolescents excluding those for doses given to children.
†Calculated by comparing each strategy to the one chosen as reference. A strategy is identified as dominating its comparator if both less expensive and more effective (i.e. under $100,000/LYG) than any other strategy, and as dominated if both more expensive and less effective than its comparator. Cost per life year gained is shown for a strategy more effective but more costly.
$Costs and outcomes are reported for 1,000,000 people, steady state situation corresponds to a period at which the full impact of the vaccination strategy considered has been reached.